These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34948294)

  • 1. Characterization of the PLN p.Arg14del Mutation in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Badone B; Ronchi C; Lodola F; Knaust AE; Hansen A; Eschenhagen T; Zaza A
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viral expression of a SERCA2a-activating PLB mutant improves calcium cycling and synchronicity in dilated cardiomyopathic hiPSC-CMs.
    Stroik DR; Ceholski DK; Bidwell PA; Mleczko J; Thanel PF; Kamdar F; Autry JM; Cornea RL; Thomas DD
    J Mol Cell Cardiol; 2020 Jan; 138():59-65. PubMed ID: 31751570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional and transcriptomic insights into pathogenesis of R9C phospholamban mutation using human induced pluripotent stem cell-derived cardiomyocytes.
    Ceholski DK; Turnbull IC; Kong CW; Koplev S; Mayourian J; Gorski PA; Stillitano F; Skodras AA; Nonnenmacher M; Cohen N; Björkegren JLM; Stroik DR; Cornea RL; Thomas DD; Li RA; Costa KD; Hajjar RJ
    J Mol Cell Cardiol; 2018 Jun; 119():147-154. PubMed ID: 29752948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early consequences of the phospholamban mutation PLN-R14del
    Maniezzi C; Eskandr M; Florindi C; Ferrandi M; Barassi P; Sacco E; Pasquale V; Maione AS; Pompilio G; Teixeira VON; de Boer RA; Silljé HHW; Lodola F; Zaza A
    Acta Physiol (Oxf); 2024 Mar; 240(3):e14082. PubMed ID: 38214033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel human R25C-phospholamban mutation is associated with super-inhibition of calcium cycling and ventricular arrhythmia.
    Liu GS; Morales A; Vafiadaki E; Lam CK; Cai WF; Haghighi K; Adly G; Hershberger RE; Kranias EG
    Cardiovasc Res; 2015 Jul; 107(1):164-74. PubMed ID: 25852082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HNO enhances SERCA2a activity and cardiomyocyte function by promoting redox-dependent phospholamban oligomerization.
    Sivakumaran V; Stanley BA; Tocchetti CG; Ballin JD; Caceres V; Zhou L; Keceli G; Rainer PP; Lee DI; Huke S; Ziolo MT; Kranias EG; Toscano JP; Wilson GM; O'Rourke B; Kass DA; Mahaney JE; Paolocci N
    Antioxid Redox Signal; 2013 Oct; 19(11):1185-97. PubMed ID: 23919584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phospholamban immunostaining is a highly sensitive and specific method for diagnosing phospholamban p.Arg14del cardiomyopathy.
    Te Rijdt WP; van der Klooster ZJ; Hoorntje ET; Jongbloed JDH; van der Zwaag PA; Asselbergs FW; Dooijes D; de Boer RA; van Tintelen JP; van den Berg MP; Vink A; Suurmeijer AJH
    Cardiovasc Pathol; 2017; 30():23-26. PubMed ID: 28759816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impairment of the ER/mitochondria compartment in human cardiomyocytes with PLN p.Arg14del mutation.
    Cuello F; Knaust AE; Saleem U; Loos M; Raabe J; Mosqueira D; Laufer S; Schweizer M; van der Kraak P; Flenner F; Ulmer BM; Braren I; Yin X; Theofilatos K; Ruiz-Orera J; Patone G; Klampe B; Schulze T; Piasecki A; Pinto Y; Vink A; Hübner N; Harding S; Mayr M; Denning C; Eschenhagen T; Hansen A
    EMBO Mol Med; 2021 Jun; 13(6):e13074. PubMed ID: 33998164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of phospholamban phosphorylation by O-GlcNAcylation: implications for diabetic cardiomyopathy.
    Yokoe S; Asahi M; Takeda T; Otsu K; Taniguchi N; Miyoshi E; Suzuki K
    Glycobiology; 2010 Oct; 20(10):1217-26. PubMed ID: 20484118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose lithium feeding increases the SERCA2a-to-phospholamban ratio, improving SERCA function in murine left ventricles.
    Hamstra SI; Kurgan N; Baranowski RW; Qiu L; Watson CJF; Messner HN; MacPherson REK; MacNeil AJ; Roy BD; Fajardo VA
    Exp Physiol; 2020 Apr; 105(4):666-675. PubMed ID: 32087034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations of phospholamban function can exhibit cardiotoxic effects independent of excessive sarcoplasmic reticulum Ca2+-ATPase inhibition.
    Schmitt JP; Ahmad F; Lorenz K; Hein L; Schulz S; Asahi M; Maclennan DH; Seidman CE; Seidman JG; Lohse MJ
    Circulation; 2009 Jan; 119(3):436-44. PubMed ID: 19139388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DWORF Extends Life Span in a PLN-R14del Cardiomyopathy Mouse Model by Reducing Abnormal Sarcoplasmic Reticulum Clusters.
    Stege NM; Eijgenraam TR; Oliveira Nunes Teixeira V; Feringa AM; Schouten EM; Kuster DWD; van der Velden J; Wolters AHG; Giepmans BNG; Makarewich CA; Bassel-Duby R; Olson EN; de Boer RA; Silljé HHW
    Circ Res; 2023 Dec; 133(12):1006-1021. PubMed ID: 37955153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant PLN-R14del Protein Interactions Intensify SERCA2a Inhibition, Driving Impaired Ca
    Vafiadaki E; Haghighi K; Arvanitis DA; Kranias EG; Sanoudou D
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remodelling of cAMP dynamics within the SERCA2a microdomain in heart failure with preserved ejection fraction caused by obesity and type 2 diabetes.
    Lai P; Hille SS; Subramanian H; Wiegmann R; Roser P; Müller OJ; Nikolaev VO; De Jong KA
    Cardiovasc Res; 2024 Mar; 120(3):273-285. PubMed ID: 38099489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac-specific overexpression of sarcolipin inhibits sarco(endo)plasmic reticulum Ca2+ ATPase (SERCA2a) activity and impairs cardiac function in mice.
    Asahi M; Otsu K; Nakayama H; Hikoso S; Takeda T; Gramolini AO; Trivieri MG; Oudit GY; Morita T; Kusakari Y; Hirano S; Hongo K; Hirotani S; Yamaguchi O; Peterson A; Backx PH; Kurihara S; Hori M; MacLennan DH
    Proc Natl Acad Sci U S A; 2004 Jun; 101(25):9199-204. PubMed ID: 15201433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unfolded Protein Response as a Compensatory Mechanism and Potential Therapeutic Target in PLN R14del Cardiomyopathy.
    Feyen DAM; Perea-Gil I; Maas RGC; Harakalova M; Gavidia AA; Arthur Ataam J; Wu TH; Vink A; Pei J; Vadgama N; Suurmeijer AJ; Te Rijdt WP; Vu M; Amatya PL; Prado M; Zhang Y; Dunkenberger L; Sluijter JPG; Sallam K; Asselbergs FW; Mercola M; Karakikes I
    Circulation; 2021 Aug; 144(5):382-392. PubMed ID: 33928785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phospholamban pentamers attenuate PKA-dependent phosphorylation of monomers.
    Wittmann T; Lohse MJ; Schmitt JP
    J Mol Cell Cardiol; 2015 Mar; 80():90-7. PubMed ID: 25562800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antiapoptotic protein HAX-1 mediates half of phospholamban's inhibitory activity on calcium cycling and contractility in the heart.
    Bidwell PA; Haghighi K; Kranias EG
    J Biol Chem; 2018 Jan; 293(1):359-367. PubMed ID: 29150445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphodiesterase 4D regulates baseline sarcoplasmic reticulum Ca2+ release and cardiac contractility, independently of L-type Ca2+ current.
    Beca S; Helli PB; Simpson JA; Zhao D; Farman GP; Jones P; Tian X; Wilson LS; Ahmad F; Chen SRW; Movsesian MA; Manganiello V; Maurice DH; Conti M; Backx PH
    Circ Res; 2011 Oct; 109(9):1024-1030. PubMed ID: 21903937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pyridone derivative activates SERCA2a by attenuating the inhibitory effect of phospholamban.
    Kaneko M; Yamamoto H; Sakai H; Kamada Y; Tanaka T; Fujiwara S; Yamamoto S; Takahagi H; Igawa H; Kasai S; Noda M; Inui M; Nishimoto T
    Eur J Pharmacol; 2017 Nov; 814():1-8. PubMed ID: 28734932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.